volume precedes price, page-13

Look for an announcement within a week or so.....re their phase 2 A trial with sciatic patients.

Specifically this trial is designed to test safety and tolerability of the pain drug. However, company have added the comment in recent disclosures, that the trial will give an indication as to effects of the drug on neuropathic pain.

In other words......they will look to determine if it works or not, as a result of this Adelaide trail.

Should the trial be successful...this stock has explosive and high medium term upside. (Although don't be to disappointed at the size of the gap following trial news- maybe will only be a few cents.)

Given a little time, investors will then reappraise the value of the company. Phase 2 positive results can see the company negotiate an initial up front payment of $50 million with any one of a number of big pharma companies. Such a deal.....aside from the likely future large revenue stream/profits from ACV1.....would have MBP with an immediate cash position TWICE its current market.

Hard to believe what I am typing......when every scrape of evidence suggests the drug trail will be successful. Suggest on positive results now.......with their cash position company would be worth $150 million NOW or 60 cents per share.